SI-BONE Inc is primarily active in the healthcare industry, specifically specializing in the development and commercialization of innovative medical devices for patients suffering from musculoskeletal disorders. The company focuses on providing minimally invasive, cutting-edge solutions for the diagnosis and treatment of conditions related to the sacroiliac joint. With their groundbreaking technology and dedication to improving patient outcomes, SI-BONE Inc has positioned itself as a leader in the healthcare sector, offering effective solutions for individuals in need of long-term relief from debilitating pain and discomfort.

The main competitors of SI-BONE Inc in the market are Zimmer Biomet Holdings Inc, Medtronic PLC, and NuVasive Inc.

SI-BONE Inc is a leading medical device company specializing in minimally invasive solutions for the treatment of sacroiliac (SI) joint dysfunction. Founded in 2008, SI-BONE has emerged as a pioneer in this field, revolutionizing the way SI joint pain is diagnosed and treated. The company's flagship product is the iFuse Implant System, which provides a durable and minimally invasive option for patients suffering from SI joint dysfunction. Backed by extensive clinical research and a commitment to innovation, SI-BONE Inc has quickly gained recognition as a trusted provider of SI joint solutions, improving the quality of life for countless patients worldwide.

SI-BONE Inc has achieved several significant milestones in their history. One noteworthy accomplishment is the FDA clearance of their iFuse Implant System, a minimally invasive surgical solution for sacroiliac joint fusion. This clearance allowed SI-BONE Inc to offer their innovative treatment to patients suffering from SI joint dysfunction. Additionally, the company went public in 2018, marking another milestone in their growth. SI-BONE Inc's dedication to research and development has led to advancements in medical technology and improved patient outcomes. They continue to make strides in the field of SI joint fusion and are committed to providing effective solutions for patients.

SI-BONE Inc is primarily present in the United States and Europe.

SI-BONE Inc represents a commitment to improving patient lives through innovative medical solutions. Their corporate philosophy revolves around providing minimally invasive technologies for the diagnosis, treatment, and management of musculoskeletal disorders. The company actively focuses on advancing the field of sacroiliac joint dysfunction (SIJD) treatment with their FDA-cleared iFuse Implant System, offering a comprehensive solution for patients suffering from SIJD. SI-BONE Inc values patient-centric care, clinical research, collaboration with healthcare professionals, and continuous innovation to enhance patient outcomes. With their dedication to addressing unmet medical needs and improving quality of life, SI-BONE Inc has emerged as a trusted leader in the field of musculoskeletal healthcare.

Analysts currently set an average price target of 25,91 USD for the SI-BONE stock (median: 25,50 USD), implying +43,7 % versus the latest price. The consensus is based on 16 analyst ratings.

SI-BONE Analyytikkojen kursstavoitteet 2026

16 analysts currently rate the SI-BONE stock: 15 recommend buying, 1 holding and 0 selling. For 2026, analysts expect SI-BONE to generate revenue of 231,62 M USD and earnings per share of −0,44 USD.

SI-BONE Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the SI-BONE share trades at 15,61 EUR (18,03 USD).

The SI-BONE share (SIBN) is listed on 3 stock exchanges, including: NASDAQ (SIBN), Frankfurt (2K3.F), München (2K3.MU).

SI-BONE Inc is a medical company specialized in the development and marketing of innovative medical products in the field of spinal surgery. The company was founded in 2008 and is headquartered in Santa Clara, California. SI-BONE Inc specializes in the treatment of degenerative spinal diseases, particularly chronic lower back pain caused by Sacroiliac Joint Dysfunction. This condition affects millions of people worldwide and can lead to significant limitations in daily life. The business model of SI-BONE Inc is based on the development and marketing of innovative medical products aimed at improving the effectiveness and efficiency of Sacroiliac Joint Fusion (SI Fusion). Through the development of new technologies and applications, the company has introduced numerous products that support both minimally invasive and traditional surgical procedures. The flagship product of SI-BONE Inc is the iFuse Implant System, which is considered the only approved method for Sacroiliac Joint Fusion. The iFuse Implant is a small, triangular implant that is inserted into the SI Joint and provides permanent fixation. The implant is made of titanium, known for its strength and biocompatibility. In addition to the iFuse Implant System, SI-BONE Inc also offers a variety of training programs and support services for surgeons and medical professionals. The company has established a comprehensive network of clinics and medical centers to facilitate access to its products and services and raise awareness of the effectiveness of Sacroiliac Joint Fusion. SI-BONE Inc has also built a strong presence in the global market and works closely with international distributors to distribute its products worldwide. The company has branches in Europe, the Middle East, Africa, Asia, and Latin America to meet the needs of its global customers. The business model of SI-BONE Inc benefits both patients and surgeons and medical professionals. By providing innovative medical products and support services, the company contributes to improving patients' quality of life and avoiding potentially irreversible damage to the spine.

odotettu liikevaihto SI-BONE on 231,62 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto SI-BONE on −19,21 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

SI-BONE:n hinta-voitto-suhde (P/E) on tällä hetkellä −40,83. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SI-BONE-osakkeen arvostusta.

SI-BONE:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,39. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii SI-BONE-osakkeen arvostuskennuslukuna.

SI-BONE:n Eulpool-laatuscore on 4/10.

SI-BONE:n ISIN on US8257041090. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

SI-BONE:n WKN on A2N7LY. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

SI-BONE:n ticker on SIBN. Tämä pörssinoteeraus käytetään SI-BONE-osakkeiden kauppaan pörssissä.

SI-BONE maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

SI-BONE kuuluu sektoriin 'Terveydenhuolto'.

SI-BONE:n osingot jaetaan valuutassa USD.